Healthcare / Medical DevicesParis
$10.46
-0.24 (-2.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $24.2M · quality 27.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$132M
P/E
N/A
•EV/EBITDA
6.3x
↓ROE
-40.6%
↓Gross Margin
70.9%
↑Debt/Equity
1.65
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.2%
FCF CAGR
—
FCF margin
5.6%
FCF / Net income
-0.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $798.7M · net income $-108.3M · FCF $44.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $798.7M | $798.7M | $851.1M | $795.7M | $769.5M |
| Net Income | $-108.3M | $-108.3M | $16.1M | $23.9M | $-41.1M |
| EBITDA | $72.6M | $72.6M | $113.0M | $102.6M | $99.3M |
| EPS | — | — | 1.07 | 1.89 | -3.25 |
| Gross Margin | 70.9% | 70.9% | 73.6% | 74.0% | 72.6% |
| Operating Margin | 1.0% | 1.0% | 5.7% | 4.9% | 5.6% |
| Net Margin | -13.6% | -13.6% | 1.9% | 3.0% | -5.3% |
| Balance Sheet | |||||
| Debt/Equity | 1.65 | 1.65 | 1.00 | 1.02 | 0.82 |
| Current Ratio | 2.49 | 2.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $44.5M | $44.5M | $24.2M | $-26.6M | $-20.1M |
| Returns | |||||
| ROE | -40.6% | -40.6% | 4.1% | 6.3% | -10.8% |
| Valuation | |||||
| P/E | — | — | 25.53 | 9.77 | — |
| EV/EBITDA | 6.31 | 6.31 | 6.10 | 5.54 | 4.94 |
| P/B | 0.49 | 0.49 | 0.87 | 0.62 | 0.58 |
| Growth & Yield | |||||
| Revenue Growth | -6.2% | -6.2% | 7.0% | 3.4% | — |
| EPS Growth | — | — | -43.3% | 158.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.7%
Start / end P/E
n/dx → n/dx
EPS bridge
1.07 → n/d
Residual
-50.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.